Bolt Biotherapeutics Inc
6LP
Company Profile
Business description
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Contact
900 Chesapeake Drive
RedwoodCA94063
USAT: +1 650 665-9295
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,158.70 | 9.80 | 0.12% |
| CAC 40 | 8,035.24 | 58.96 | -0.73% |
| DAX 40 | 22,827.56 | 171.59 | -0.75% |
| Dow JONES (US) | 41,710.11 | 243.21 | -0.58% |
| FTSE 100 | 8,644.75 | 57.24 | -0.66% |
| HKSE | 23,689.72 | 530.23 | -2.19% |
| NASDAQ | 17,581.01 | 110.61 | -0.63% |
| Nikkei 225 | 37,677.06 | 74.82 | -0.20% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,623.46 | 39.43 | -0.70% |
| S&P/ASX 200 | 7,931.20 | 12.30 | 0.16% |
| SSE Composite Index | 3,364.83 | 44.12 | -1.29% |